Leap Therapeutics (DB:5MC) - Aandelenkoers, Nieuws & Analyse

5MC Overzicht aandelen

Leap Therapeutics, Inc. is een biofarmaceutisch bedrijf dat antilichaamtherapieën voor de behandeling van kanker verwerft en ontwikkelt.

Over het bedrijf

5MC fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Aandeelhouders zijn het afgelopen jaar verwaterd

Leap Therapeutics, Inc. Concurrenten

4SC

DB:VSC

€61.5m

Heidelberg Pharma

XTRA:HPHA

€111.9m

Medigene

XTRA:MDG1

€25.0m

2invest

XTRA:2INV

€59.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Leap Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$3.36
52 Week Hoogtepunt	US$4.54
52 Week Laag	US$1.08
Bèta	0.27
11 maand verandering	61.54%
3 maanden verandering	75.92%
1 Jaar Verandering	147.06%
33 jaar verandering	-84.30%
5 jaar verandering	-53.01%
Verandering sinds IPO	-94.92%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	5MC	DE Biotechs	DE Markt
7D	-0.6%	0.7%	1.1%
1Y	147.1%	-17.7%	12.5%

Rendement versus industrie: 5MC overtrof de German Biotechs industrie, die het afgelopen jaar een rendement -17.7 % opleverde.

Rendement versus markt: 5MC overtrof de German markt, die het afgelopen jaar een rendement opleverde van 12.5 %.

Prijsvolatiliteit

Is 5MC's price volatile compared to industry and market?
5MC volatility
5MC Average Weekly Movement	14.2%
Biotechs Industry Average Movement	5.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van 5MC is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 14% ) van 5MC is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2011	54	Doug Onsi	www.leaptx.com

Leap Therapeutics, Inc, een biofarmaceutisch bedrijf, verwerft en ontwikkelt antilichaamtherapieën voor de behandeling van kanker. Haar belangrijkste productkandidaten zijn DKN-01, een monoklonaal antilichaam dat Dickkopf-gerelateerd proteïne 1 remt, dat in meerdere lopende klinische onderzoeken wordt onderzocht voor de behandeling van slokdarm- en gynaecologische kankers; en FL-301, een monoklonaal antilichaam dat zich richt tegen cellen die Claudin18.2 tot expressie brengen op hun celoppervlak en dat zich in fase II van het klinisch onderzoek bevindt, evenals twee preklinische antilichaamprogramma's, FL-302 en FL-501. Leap Therapeutics, Inc. heeft een optie- en licentieovereenkomst met NovaRock, Adimab en BeiGene, Ltd.

Leap Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Leap Therapeutics zich tot de beurswaarde?
5MC fundamentele statistieken
Marktkapitalisatie	€131.48m
Inkomsten(TTM)	-€55.89m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-2.2x

Koers/Winstverhouding

Is 5MC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
5MC resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$60.34m
Inkomsten	-US$60.34m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.58
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 5MC op de lange termijn?

Bekijk historische prestaties en vergelijking

5MC Overzicht aandelen

Beloningen

Risicoanalyse

Leap Therapeutics, Inc. Concurrenten

DB:VSC

€61.5m

XTRA:HPHA

€111.9m

XTRA:MDG1

€25.0m

XTRA:2INV

€59.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Recent updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

First half 2022 earnings released

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

First quarter 2022 earnings released: US$0.092 loss per share (vs US$0.12 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

Insufficient new directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.55 loss in 1Q 2020)

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue misses expectations

New 90-day high: €2.18

New 90-day high: €2.00

New 90-day low: €1.27

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day high: €1.84

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - €1.50

New 90-day low - €1.52

Leap Therapeutics, Inc.(NasdaqGM:LPTX) dropped from Russell Microcap Value Index

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Leap Therapeutics, Inc. Samenvatting

0.0x

-2.2x

Inkomsten en omzet